Poland will implement a new list of 282 medicines facing potential shortages from April 8th, including insulin, Ozempic, and ADHD medications.
New Shortage List Takes Effect
As of April 8th, 2024, a new list of medicines at risk of shortage will be enforced. The list comprises 282 products, ranging from insulin and diabetes medications to ADHD treatments, pain relievers, and the HPV vaccine.
This list, based on actual shortages, aims to limit the export of medicines from Poland, but also highlights existing systemic issues. Patients with chronic conditions may be directly affected.
List Based on Real Shortages, Not Projections
The Ministry of Health published the new list of products at risk of shortage on March 31st. Compared to previous months, the list is longer, suggesting the problem of medicine availability is worsening, not being resolved.
The list is not a precautionary measure; it includes products already unavailable in some pharmacies, indicating a reactive rather than preventative approach.
The 5% Rule and Actual Pharmacy Shortages
The criteria for adding medicines to the list are clearly defined, based on data from pharmacies, not forecasts or political decisions. A medicine is added if it is unavailable in at least 5% of pharmacies.
This means the list covers medicines already beginning to disappear from shelves. Export restrictions aim to curb outflow, but do not necessarily increase domestic availability.
Insulin, Ozempic, and ADHD Medications Most Vulnerable
The inclusion of commonly used medications for chronic conditions is particularly concerning. These are not niche products, but essential therapies.
Availability is a key issue, as suitable generic alternatives are not always available or easily implemented.
Shortages Extend Beyond Chronic Illnesses
The new list demonstrates a broader problem, extending to areas previously considered stable. It includes the HPV vaccine and medications for children.
This indicates the issue affects not only patients with chronic diseases, but also children and those undergoing specialized treatment.
20 Commonly Known Medicines on the Shortage List
Among the 282 items, several are familiar to patients, including insulin, ADHD medications, and strong pain relievers. Examples include Lantus, Humalog, Ozempic, Medikinet, and MST Continus.
New Rules, Uncertain Availability
The implementation of the list primarily means a ban on exporting these medicines abroad and increased control over their distribution. However, it does not guarantee immediate availability in pharmacies.
The list acts more as an “export brake” than a solution to supply problems. Patients may need to be more flexible and plan ahead.
Impact on Patients: Potential Treatment Changes
A diabetes patient using a specific insulin may find it unavailable in their local pharmacy, requiring them to search elsewhere or consider switching medications. This could necessitate a doctor’s visit and potential treatment instability.
Similar challenges exist for patients requiring ADHD or chronic pain medications, potentially disrupting treatment continuity.
Price Differences and Export Drive Shortages
The root of the problem lies in price discrepancies between countries. Medicines in Poland are often cheaper than in Western Europe, incentivizing export.
This creates a reverse distribution chain where medicines purchased in Poland are sold abroad at higher prices. The shortage list aims to curb this, but without increased production and supply, the problem recurs.
What to Do When a Medicine is Unavailable
While there is no formal obligation, adapting to the new situation is necessary. Patients should try different pharmacies, ask about alternative medications, and consult with their doctor.
The list does not automatically mean a medicine will disappear from the market, but its availability is threatened and may vary by region.